Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2014; 20(33): 11574-11585
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11574
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11574
Table 1 Main genetic and epigenetic alterations in gastric cancer tissues and their clinical application as biomarkers
Alteration | Type of alteration | Clinical application | Ref. |
HER-2 amplification | Genetic | Prognostic and therapeutic | [34-40] |
MYC amplification | Genetic | Progression and metastasis | [52] |
TP53 Arg72Pro | Genetic | Risk predictor, prognostic | [63-67,69-72] |
CDH1 -160 C>A | Genetic | Risk predictor | [76-78] |
CDH1 hypermethylation | Epigenetic | Prognostic, metastasis | [167,170,171] |
p16 hypermethylation | Epigenetic | Diagnostic, prognostic and therapeutic | [156-160] |
Table 2 miRNAs differently expressed in gastric cancer tissues and their clinical application
miRNA | Level of expression | Clinical application | Ref. |
miR-301a | Up-regulated | Progression and prognostic | [127] |
miR-29 family | Down-regulated | Prognostic and therapeutic | [128] |
miR-146a | Down-regulated | Metastasis | [129] |
miR-10b | Up-regulated | Progression and prognostic | [130] |
miR-107 | Up-regulated | Prognostic | [131] |
miR-345 + miR-142 | Up-regulated (miR-345) and Down-regulated (miR-142) | Recurrence and progression | [132] |
let-7i | Down-regulated | Prognostic and therapeutic | [133] |
miR-221 | Up-regulated | Progression, prognostic and therapeutic | [125,134] |
miR-148a | Down-regulated | Prognostic | [135] |
miR-155 | Down-regulated | Progression and metastasis | [136] |
miR-129-2-3p | Down-regulated | Progression | [137] |
miR-181b | Up-regulated | Prognostic | [138] |
miR-21 | Up-regulated | Prognostic | [138,139] |
Table 3 miRNAs differently expressed in body fluids from gastric cancer patients and their clinical application
miRNA | Body fluid | Level of expression | Clinical application | Ref. |
miR-200c | Blood | Up-regulated | Progression and survival | [140] |
miR-421 | Gastric Juice | Up-regulated | Screening | [141] |
miR-21 | Gastric Juice | Up-regulated | Screening | [142] |
miR-106a | Gastric Juice | Up-regulated | Screening | [142] |
miR-129-1-3p | Gastric Juice | Down-regulated | Screening | [137] |
miR-129-2-3p | Gastric Juice | Down-regulated | Screening | [137] |
miR-335 | Blood | Up-regulated | Recurrence and prognostic | [143] |
miR-221 | Serum | Up-regulated | Screening | [144] |
miR-744 | Serum | Up-regulated | Screening | [144] |
miR-376c | Serum | Up-regulated | Screening | [144] |
miR-199a-3p | Plasma | Up-regulated | Progression, screening | [145] |
- Citation: Pinheiro DDR, Ferreira WAS, Barros MBL, Araújo MD, Rodrigues-Antunes S, Borges BDN. Perspectives on new biomarkers in gastric cancer: Diagnostic and prognostic applications. World J Gastroenterol 2014; 20(33): 11574-11585
- URL: https://www.wjgnet.com/1007-9327/full/v20/i33/11574.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i33.11574